title: Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation.
abstract: BACKGROUND
  A prospective, semi-randomized, open, clinical study was conducted to compare ovarian response, pregnancy outcome and delivery rates using two recombinant FSH preparations (Gonal-F and Puregon) for IVF.
  
  
  METHODS
  We analysed stimulation parameters and outcome data in 812 initiated treatment cycles where 292 women used Gonal-F and 200 used Puregon. Embryo transfer was carried out in 676 cycles. In the two preparation groups we also compared 170 women previously treated with FSH for IVF with 266 previously untreated.
  
  
  RESULTS
  The pregnancy rate with Gonal-F was 26% and with Puregon 28%. Delivery rates were identical, 22%. Clinical pregnancy and delivery rates per cycle with embryo transfer in earlier untreated women were 29.0 and 24.0%, whereas in previously treated women they were 23.5 and 18.8% respectively. After repeated cycles, delivery frequencies consecutively decreased, independent of the FSH preparation used.
  
  
  CONCLUSIONS
  Gonal-F and Puregon seem to be equally potent in achieving follicular development and equally effective, in terms of delivery rates, for use in an IVF programme. Repeated cycles resulted in equally large consecutive decreases in delivery rates, regardless of preparation choice, but were considered worthwhile for up to three stimulation cycles in selected patients.
authors.affiliation: Reproductive Medical Centre, Department of Women and Child Health, Division of Obstetrics and Gynaecology, Karolinska Hospital, Stockholm, Sweden. jonas.harlin@ks.se
authors.forename: Jonas
authors.initials: J
authors.lastname: Harlin
authors.forename: A
authors.initials: A
authors.lastname: Aanesen
authors.forename: G
authors.initials: G
authors.lastname: Csemiczky
authors.forename: H
authors.initials: H
authors.lastname: Wramsby
authors.forename: G
authors.initials: G
authors.lastname: Fried
mesh_terms: D000328:Adult; D015925:Cryopreservation; D036861:Delivery, Obstetric / Q000706:statistics & numerical data*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005306:Fertilization; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D043373:Follicle Stimulating Hormone, Human; D006728:Hormones / Q000097:blood; D006801:Humans; D007246:Infertility / Q000628:therapy*; D008297:Male; D010053:Ovary / Q000187:drug effects*; D011247:Pregnancy; D018873:Pregnancy Rate; D011994:Recombinant Proteins / Q000627:therapeutic use; D013076:Sperm Count; D020554:Sperm Injections, Intracytoplasmic
chemical_list: D043373:Follicle Stimulating Hormone, Human; D006728:Hormones; D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone